ES2114423B1 - Nuevas composiciones farmaceuticas de liberacion de farmaco controlada por difusion-osmosis y procesos para preparar las mismas. - Google Patents

Nuevas composiciones farmaceuticas de liberacion de farmaco controlada por difusion-osmosis y procesos para preparar las mismas.

Info

Publication number
ES2114423B1
ES2114423B1 ES09402519A ES9402519A ES2114423B1 ES 2114423 B1 ES2114423 B1 ES 2114423B1 ES 09402519 A ES09402519 A ES 09402519A ES 9402519 A ES9402519 A ES 9402519A ES 2114423 B1 ES2114423 B1 ES 2114423B1
Authority
ES
Spain
Prior art keywords
diffusion
pharmaceutical
hydrophyl
prepare
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09402519A
Other languages
English (en)
Other versions
ES2114423A1 (es
Inventor
Pal Fekete
Maria Kiraly
Gabor Sipos
Zsuzsanna Jambor
Gyorgy Ujfalussy
Magdolna Gora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egyt Gyogyszervegyeszeti Gyar
Egis Pharmaceuticals PLC
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar, Egis Pharmaceuticals PLC filed Critical Egyt Gyogyszervegyeszeti Gyar
Publication of ES2114423A1 publication Critical patent/ES2114423A1/es
Application granted granted Critical
Publication of ES2114423B1 publication Critical patent/ES2114423B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

NUEVAS COMPOSICIONES FARMACEUTICAS DE LIBERACION DE FARMACO CONTROLADA POR DIFUSION-OSMOSIS Y PROCESOS PARA PREPARAR LAS MISMAS. LA INVENCION SE REFIERE A UN NUEVO COMPUESTO FARMACEUTICO DE LIBERACION DE FARMACOS CONTROLADA POR DIFUSION-OSMOSIS, QUE CONTIENE UN NUCLEO DE TABLETA DE UNA O DOS CAPAS, INCLUYENDO UNA PELICULA DE RECUBRIMIENTO POLIMERICO, UNA SUSTANCIA TERAPEUTICAMENTE ACTIVA Y UN POLIMERO HIDROFILO; CON UNO O MAS AGUJEROS EN LA PELICULA DE RECUBRIMIENTO QUE ESTA EN CONTACTO CON EL NUCLEO, O CON EL POLIMERO HIDROFILO, QUE COMPRENDE UN COPOLIMERO DE METACRILATO AMONICO COMO MATERIAL DE RECUBRIMIENTO Y COMO POLIMERO HIDROFILO HIDROXIPROPIL-METIL-CELULOSA. EL COMPUESTO DESCRITO ES UTIL PARA PREPARAR TABLETAS DE LIBERACION DE FARMACO CONTROLADA QUE CONTIENEN COMO SUBSTANCIA ACTIVA FARMACOS UTILIZADOS PARA LAS ENFERMEDADES DEL CORAZON Y CIRCULATORIAS O QUE ACTUAN SOBRE EL SISTEMA NERVIOSO CENTRAL. LA INVENCION SE REFIERE ADEMAS A UN PROCESO PARA LA PREPARACION DE LOS COMPUESTOS ARRIBA INDICADOS.
ES09402519A 1993-12-09 1994-12-09 Nuevas composiciones farmaceuticas de liberacion de farmaco controlada por difusion-osmosis y procesos para preparar las mismas. Expired - Lifetime ES2114423B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9303504A HU213407B (en) 1993-12-09 1993-12-09 Process for producing tablet with diffusive-osmotic release

Publications (2)

Publication Number Publication Date
ES2114423A1 ES2114423A1 (es) 1998-05-16
ES2114423B1 true ES2114423B1 (es) 1999-07-01

Family

ID=10984230

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09402519A Expired - Lifetime ES2114423B1 (es) 1993-12-09 1994-12-09 Nuevas composiciones farmaceuticas de liberacion de farmaco controlada por difusion-osmosis y procesos para preparar las mismas.

Country Status (21)

Country Link
US (1) US5543155A (es)
EP (1) EP0662321B1 (es)
JP (1) JPH07277957A (es)
KR (1) KR950016714A (es)
AT (1) ATE185693T1 (es)
BE (1) BE1009867A3 (es)
BG (1) BG61592B1 (es)
CA (1) CA2137426A1 (es)
CZ (1) CZ288014B6 (es)
DE (1) DE69421263T2 (es)
ES (1) ES2114423B1 (es)
FR (1) FR2713484B1 (es)
GR (1) GR1002349B (es)
HR (1) HRP940979A2 (es)
HU (1) HU213407B (es)
IT (1) IT1271122B (es)
PL (1) PL306181A1 (es)
RU (1) RU2133605C1 (es)
SK (1) SK279735B6 (es)
UA (1) UA34458C2 (es)
YU (1) YU71894A (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
BR9708625A (pt) 1996-04-12 1999-08-03 Novo Nordisk As Grãnulo contendo enzina processo para a produção do mesmo composição detergente composição para ração animal composição para panificação e utilização de grãnulos
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
KR100522248B1 (ko) * 1997-05-29 2006-02-01 동아제약주식회사 이중제어방출막구조의경구서방성제제및그제조방법
US6485748B1 (en) 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
CA2354057C (en) 1998-12-11 2009-02-10 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
MXPA02006335A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
DE60038698T2 (de) * 1999-12-23 2009-05-07 Pfizer Products Inc., Groton Hydrogel-gesteuerte dosierungsform
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
JP2003521507A (ja) 2000-02-04 2003-07-15 ディポメド，インコーポレイティド ゼロ次薬物放出に接近するシェル−コア剤形
US6268368B1 (en) * 2000-03-01 2001-07-31 American Pharmaceuticals International Anionic exchange polymer complexes of buspirone
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20040062787A1 (en) * 2001-12-17 2004-04-01 Daley William Lionel Therapeutic combination of amlodipineand benazepril/benazeprilat
US6419903B1 (en) * 2001-08-20 2002-07-16 Colgate Palmolive Company Breath freshening film
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
BR0306870A (pt) 2002-01-15 2004-11-03 Ucb Farchim Sa Composição farmacêutica oral, e, método para preparar a mesma
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
PE20050335A1 (es) * 2003-08-07 2005-06-01 Sb Pharmco Inc Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
WO2006007354A2 (en) * 2004-06-28 2006-01-19 Alza Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
GB2421431B (en) * 2004-12-24 2007-10-10 Aquasol Ltd Dosing systems
US8431156B2 (en) * 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition
US20070031496A1 (en) * 2005-08-04 2007-02-08 Edgren David E Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
US20070128281A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US20070128280A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
US20110142905A1 (en) * 2008-08-14 2011-06-16 Bioneer A/S Coated tablets with remaining degradation surface over the time
TWI478733B (zh) * 2009-05-13 2015-04-01 Wyeth Llc 突釋藥物釋放組合物
IN2015DN04161A (es) 2012-10-16 2015-10-16 Ranbaxy Lab Ltd
CN104721051B (zh) * 2014-12-17 2018-03-20 镇江杏林医疗科技有限公司 理疗贴及其柱形膏的制作方法
WO2016192680A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Dosage forms and use thereof
WO2019137200A1 (en) 2018-01-09 2019-07-18 Triastek, Inc. Oral drug dosage forms comprising a fixed-dose of an adhd non-stimulant and an adhd stimulant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
DE3438291A1 (de) * 1984-10-19 1986-04-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US5271946A (en) * 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine

Also Published As

Publication number Publication date
CA2137426A1 (en) 1995-06-10
UA34458C2 (uk) 2001-03-15
ES2114423A1 (es) 1998-05-16
EP0662321A1 (en) 1995-07-12
YU71894A (sh) 1997-03-07
BG61592B1 (bg) 1998-01-30
IT1271122B (it) 1997-05-26
ITMI942484A0 (it) 1994-12-09
HUT69397A (en) 1995-09-28
JPH07277957A (ja) 1995-10-24
DE69421263D1 (de) 1999-11-25
RU2133605C1 (ru) 1999-07-27
CZ309994A3 (en) 1995-07-12
US5543155A (en) 1996-08-06
KR950016714A (ko) 1995-07-20
SK279735B6 (sk) 1999-03-12
FR2713484B1 (fr) 1997-12-12
SK152494A3 (en) 1995-07-11
ATE185693T1 (de) 1999-11-15
RU94043798A (ru) 1996-11-10
HU213407B (en) 1997-06-30
GR1002349B (el) 1996-05-29
BE1009867A3 (fr) 1997-10-07
ITMI942484A1 (it) 1996-06-09
CZ288014B6 (cs) 2001-04-11
HU9303504D0 (en) 1994-04-28
DE69421263T2 (de) 2000-05-11
PL306181A1 (en) 1995-06-12
FR2713484A1 (fr) 1995-06-16
EP0662321B1 (en) 1999-10-20
BG99252A (en) 1995-09-29
HRP940979A2 (en) 1997-02-28

Similar Documents

Publication Publication Date Title
ES2114423B1 (es) Nuevas composiciones farmaceuticas de liberacion de farmaco controlada por difusion-osmosis y procesos para preparar las mismas.
DK469989D0 (da) Farmaceutisk praeparat
CZ281991B6 (cs) Způsob výroby transdermálního therapeutického systému
ES2060593T3 (es) Sistema de aporte de farmacos.
FI906344A (fi) Kontrollerat frigoerande farmaceutiskt preparat.
ES2106818T3 (es) Composicion multicapa que contiene antagonistas de histamina o secotina.
DK1477187T3 (da) Formulering til kontrolleret frigivelse af medikamenter ved at kombinere hydrofile og hydrofobe stoffer
BRPI0507683A (pt) dose unitária com liberação de formulação farmacêutica com liberação controlada, processo para sua preparação, bem como uso de um copolìmero de poli(acrilato de etila, metacrilato de metila) neutro
ES2037082T3 (es) Una composicion para la liberacion controlada de un farmaco.
ES2164837T3 (es) Formulacion oral de olanzapina.
NO175405C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat med sakte frigivelse, som ikke er et injeksjonsfluid
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
EA200200595A1 (ru) Лекарственная форма с высвобождением лекарства под действием гидрогеля
PE27999A1 (es) Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente
ES2091654T3 (es) Sistema efervescente que contiene un ingrediente activo farmaceutico sensible a alcalis y/o metales, y procedimiento para su produccion.
CZ587488A3 (en) Nicotine magazine
SK279300B6 (sk) Prípravok na uvoľňovanie látok z tavných kontaktný
UY28189A1 (es) Sistema terapéutico transdérmico estable a los rayos uv.
SV1998000119A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa. ref. lea 32671-sv
AR005353A1 (es) Formulacion de hormona para crecimiento animal de liberacion sostenida, y un procedimiento para la preparacion de la misma
ES2052816T3 (es) Una composicion para revestir granulos de farmacos.
AR026038A1 (es) Sistema terapeutico transdermal para la administracion de acido acetilsalicilico y/o acido salicilico y proceso de fabricacion
ES2115705T3 (es) Forma retardada para producto farmaceuticamente activo.
AR103296A2 (es) Tableta o gránulo donde la liberación del ingrediente activo es controlada
ATE399001T1 (de) Sphäroide, deren herstellungsverfahren und sphäroidenhaltige arzneimittel

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980516

Kind code of ref document: A1

Effective date: 19980516